| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| |
|
|
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Linear enhancement after radio-frequency ablation for hepatocellular carcinoma: is it a sign of recurrence? |
|
|
|
|
| |
Takahashi M, Maruyama H, Shimada T, Kamezaki H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O. Ultrasound Med Biol. 2012 Nov;38(11):1902-10. doi: 10.1016/j.ultrasmedbio.2012.07.003. |
|
| |
|
|
| |
Source
Department of Medicine and Clinical Oncology, Chiba University Graduate School of Medicine, Chiba, Japan.
Abstract
This prospective study was performed in 179 hepatocellular carcinoma (HCC) lesions treated by radio-frequency ablation (RFA) to explore the clinical outcome of "linear enhancement" on contrast-enhanced sonogram. Thirty-three lesions (18.4%) showed linear enhancement, a linear-shaped positive enhancement in the RFA-treated area. Seventeen of them were followed up with no treatment (remaining 16; dropout in eight, additional RFA in six and ineffective treatment in two) and three lesions (3/17, 17.6%) showed local tumor progression corresponding to linear enhancement at 7, 14, 19 months after RFA. Although there was no significant difference in local recurrence rate between the lesions with (3/17) and without linear enhancement (10/35), local tumor progression inside the ablation zone occurred only in the lesions with linear enhancement. In conclusion, linear enhancement inside the RFA-treated area should be followed up within 7 months because it has a risk of local tumor progression. Histology of linear enhancement and its influence on distant recurrence remain to be solved.
|
|
|
|
| |
| |
|
